Alkermes launches 180-patient Phase 2 ALKS 7290 trial testing orexin activation in major depression
Alkermes starts a 180-patient Phase 2 ALKS 7290 depression trial, testing orexin activation alongside antidepressants and assessing safety.
Pharma & Biotech
Pharma & Biotech
Why UroGen Pharma is looking beyond bladder cancer with IntraGel’s cisplatin-loaded SRGel platform
UroGen Pharma will invest up to $7 million in IntraGel while securing an option on TumoCure and potential rights to three additional SRGel oncology programmes.
Medical Devices & Diagnostics
Nanochon can now test Chondrograft in Panama, but five patients could decide what happens next
Nanochon gains Panama authorization for a five-patient Chondrograft study as its cartilage implant moves deeper into first-in-human testing.
Features & Analysis
Will ICON’s Anthropic collaboration reduce clinical trial delays and protocol amendments?
ICON and Anthropic will build Claude-powered clinical trial tools inside Orbis, targeting site selection, enrolment risk and protocol design.
Medical Devices & Diagnostics
How could CyPath Lung fit into pulmonary nodule evaluation after low-dose CT screening?
bioAffinity’s CyPath Lung framework targets pulmonary nodule decisions, but adoption still depends on prospective validation and payer support.
Pharma & Biotech
AnHorn Medicines doses first participant in Phase 1 AH-008 CIPN prevention trial
AnHorn Medicines doses the first participant in a Phase 1 AH-008 study, opening a cautious clinical test of chemotherapy neuropathy prevention.
Pharma & Biotech
Why United Therapeutics’ FDA-cleared UHeart trial could redefine xenotransplantation risk
Find out how United Therapeutics’ FDA-cleared UHeart trial could reshape xenotransplantation for end-stage heart failure patients.